The landscape of weight-loss treatment has been significantly altered by GLP-1 drugs, and the recent approval of the first oral pill in the UK is expected to further increase their prevalence. Dr. Clair Grainger, an online doctor at Superdrug, has provided answers to frequently asked questions regarding this new iteration of medication, addressing concerns ranging from hair loss to the impact on fertility.

Hair Loss Concerns

One question that has arisen is the potential for hair loss associated with weight-loss pills. Dr. Grainger explained that increased hair shedding is more likely a consequence of the weight loss itself rather than the medication. Rapid weight loss can cause hair follicles to enter a temporary resting phase, leading to increased shedding. This type of hair loss is typically temporary, with hair growth often returning to normal as the body adjusts.

There is currently no evidence to suggest that the oral version of the drug carries a higher risk of hair loss compared to injectable GLP-1 medications. The most probable cause remains the rate of weight change, regardless of the delivery method.

Impact on Sex Drive and Fertility

While changes in libido are not a direct side effect of oral weight-loss medication, some patients report experiencing differences. Dr. Grainger noted that common side effects such as nausea or fatigue may temporarily decrease interest in sex. Conversely, weight loss can lead to improved energy levels and confidence, potentially boosting libido. Some individuals may experience an initial decrease in sex drive that improves later, while others notice no change.

Regarding fertility, some healthcare professionals may recommend weight loss for overweight patients to improve conception chances or IVF success. However, women actively trying to conceive are advised not to use weight-loss medication. Due to the drug's extended presence in the body, it is recommended to stop treatment at least two months before attempting to become pregnant. Patients considering fertility treatment should consult with their doctor or a fertility specialist.

Managing Side Effects and Drug Interactions

Concerns about vomiting after taking the pill are addressed by advising patients not to take an additional dose on the same day, even if absorption is suspected. This could increase the risk of side effects. Patients are instructed to follow their information leaflet and resume their normal dosing schedule the following day, seeking medical advice for severe symptoms.

Oral weight-loss drugs are not known to directly interfere with oral contraceptives. However, if vomiting or diarrhea occurs, the absorption of other medications, including birth control pills, can be affected. Patients are advised to consult their contraceptive medication's guidance and their doctor. The oral pill should be taken at least 30 minutes before any other oral medication.

Alcohol Consumption and Missed Doses

Alcohol does not appear to impede the medication's effectiveness, but it can exacerbate common side effects like nausea and headaches. Additionally, alcohol can increase appetite and make healthy food choices more challenging, potentially leading to dizziness or weakness when combined with the medication.

If a dose is missed, patients should not double up on the next day or take the forgotten dose later. Instead, they should take their next scheduled dose as normal. Adherence to specific medication instructions is crucial, as guidance can vary.

Other Medications

Before starting weight-loss treatment, it is essential to discuss all current medications with a healthcare professional. While many medications can be taken concurrently, prescribers need to be aware of all prescription drugs, over-the-counter treatments, and supplements. Some medications may require monitoring or dose adjustments, particularly diabetes medications, blood thinners, levothyroxine, other GLP-1 medications, and drugs like lithium, digoxin, and ciclosporin. Patients are urged to inform their prescriber of everything they are taking to ensure safety.